Latent, a company focused on automating medication approval workflows, has raised $80 million in Series A funding. The round was co-led by Spark Capital and Transformation Capital, with participation from General Catalyst, McKesson Ventures, Y Combinator, and Conviction. The company plans to use the funding to expand its platform, grow its workforce, and deepen partnerships with health systems.
Latent’s clinical AI software processes electronic health record (EHR) data to streamline medication access. The platform interprets drug approval criteria, analyzes patient data, and orchestrates workflows to reduce delays in prior authorization and medication management. By automating these processes, Latent aims to improve speed and efficiency in getting patients access to prescribed treatments.
The company has scaled rapidly, growing from four to more than 45 health system partners and now serving half of the top 20 U.S. health systems, including Yale New Haven Health, Mount Sinai, Vanderbilt Health, UCSF Health, and UCLA Health. This growth reflects rising demand for tools that address administrative bottlenecks in medication access.
Latent operates in a broader digital health market focused on improving prescription access and affordability. Competitors and adjacent players include companies like Amazon Pharmacy, which is expanding same-day delivery, and Interra Health and Scripta Insights, which focus on pricing transparency, navigation, and prescribing optimization.
Click here to read the original news story.